Avshesh Mishra1, Anshika Srivastava1, Surendra Kumar1, Tulika Mittal2, Naveen Garg2, Surendra Kumar Agarwal3, Shantanu Pande3, Balraj Mittal4. 1. Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow 226014, UP, India. 2. Department of Cardiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow 226014, UP, India. 3. Department of CVTS, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow 226014, UP, India. 4. Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow 226014, UP, India. Electronic address: balraj@sgpgi.ac.in.
Abstract
BACKGROUND: Left ventricular dysfunction (LVD) with subsequent congestive heart failure (CHF) constitutes the final common pathway for a host of cardiac disorders. The impaired LV function develops in response to an ischemic insult followed by a fall in cardiac output that leads to activation of renin-angiotensin-system (RAS). Angiotensin II type I receptor (AT1), which mediate the vasoconstrictive and salt-conserving actions of the RAS, represent interesting candidate genes for cardiovascular diseases. Therefore, we conducted an association study between single nucleotide polymorphism (SNP) in AT1 gene and LVD in CAD patients. METHODS AND RESULTS: The present study recruited a total of 950 subjects including 720 angiography confirmed CAD patients and 230 healthy controls. Among 720 CAD patients, 229 with reduced left ventricle ejection fraction (LVEF≤45%) were categorized as LVD. The AT1 (A1166C, rs5186) polymorphism was determined by ARMS-PCR. Our results showed that the frequency of AT1 1166AC and CC genotypes were significantly higher in LVD patients in comparison to non-LVD (LVEF >45%) patients (p value = 0.003; OR = 1.81 and p value <0.001; OR = 4.33). Further analysis showed that AT1 A1166C polymorphism was significantly associated with LV end diastole (p-value = 0.031), end systole (p-value = 0.038) dimensions, and mean LVEF (p-value = 0.035). Moreover, on comparing the AT1 A1166C polymorphism in CAD patients with healthy controls, we did not find any association both at genotypic and allelic level (p value = 0.927; OR = 1.04 and p value = 0.219; OR = 0.83) respectively. CONCLUSIONS: Our study suggests that AT1 A1166C polymorphism may play significant role in conferring genetic susceptibility of LVD.
BACKGROUND:Left ventricular dysfunction (LVD) with subsequent congestive heart failure (CHF) constitutes the final common pathway for a host of cardiac disorders. The impaired LV function develops in response to an ischemic insult followed by a fall in cardiac output that leads to activation of renin-angiotensin-system (RAS). Angiotensin II type I receptor (AT1), which mediate the vasoconstrictive and salt-conserving actions of the RAS, represent interesting candidate genes for cardiovascular diseases. Therefore, we conducted an association study between single nucleotide polymorphism (SNP) in AT1 gene and LVD in CAD patients. METHODS AND RESULTS: The present study recruited a total of 950 subjects including 720 angiography confirmed CAD patients and 230 healthy controls. Among 720 CAD patients, 229 with reduced left ventricle ejection fraction (LVEF≤45%) were categorized as LVD. The AT1 (A1166C, rs5186) polymorphism was determined by ARMS-PCR. Our results showed that the frequency of AT1 1166AC and CC genotypes were significantly higher in LVD patients in comparison to non-LVD (LVEF >45%) patients (p value = 0.003; OR = 1.81 and p value <0.001; OR = 4.33). Further analysis showed that AT1 A1166C polymorphism was significantly associated with LV end diastole (p-value = 0.031), end systole (p-value = 0.038) dimensions, and mean LVEF (p-value = 0.035). Moreover, on comparing the AT1 A1166C polymorphism in CAD patients with healthy controls, we did not find any association both at genotypic and allelic level (p value = 0.927; OR = 1.04 and p value = 0.219; OR = 0.83) respectively. CONCLUSIONS: Our study suggests that AT1 A1166C polymorphism may play significant role in conferring genetic susceptibility of LVD.
Authors: M Hamon; C Amant; C Bauters; F Richard; N Helbecque; E McFadden; J M Lablanche; M Bertrand; P Amouyel Journal: Heart Date: 1997-06 Impact factor: 5.994
Authors: A Busjahn; H Knoblauch; M Knoblauch; J Bohlender; M Menz; H D Faulhaber; A Becker; H Schuster; F C Luft Journal: Hypertension Date: 1997-01 Impact factor: 10.190
Authors: A Benetos; S Gautier; S Ricard; J Topouchian; R Asmar; O Poirier; E Larosa; L Guize; M Safar; F Soubrier; F Cambien Journal: Circulation Date: 1996-08-15 Impact factor: 29.690
Authors: S Takami; T Katsuya; H Rakugi; N Sato; Y Nakata; A Kamitani; T Miki; J Higaki; T Ogihara Journal: Am J Hypertens Date: 1998-03 Impact factor: 2.689
Authors: A P Osterop; M J Kofflard; L A Sandkuijl; F J ten Cate; R Krams; M A Schalekamp; A H Danser Journal: Hypertension Date: 1998-11 Impact factor: 10.190
Authors: L Tiret; A Bonnardeaux; O Poirier; S Ricard; P Marques-Vidal; A Evans; D Arveiler; G Luc; F Kee; P Ducimetière Journal: Lancet Date: 1994-10-01 Impact factor: 79.321
Authors: A Bonnardeaux; E Davies; X Jeunemaitre; I Féry; A Charru; E Clauser; L Tiret; F Cambien; P Corvol; F Soubrier Journal: Hypertension Date: 1994-07 Impact factor: 10.190
Authors: Alexandra Dadarlat-Pop; Dana Pop; Lucia Procopciuc; Adela Sitar-Taut; Dumitru Zdrenghea; Gyorgy Bodizs; Raluca Tomoaia; Diana Gurzau; Florina Fringu; Silvana Susca-Hojda; Anca D Buzoianu Journal: Int J Gen Med Date: 2021-05-06